HIV-1 BED: A Simple Serological Assay for Detecting Recent Infection and Estimating Incidence of Multiple, Worldwide HIV-1 Subtypes


This CDC developed invention is a simple enzyme immunoassay that detects increasing levels of anti-HIV-IgG after seroconversion and can be used for detection of HIV-1 infection. The assay, termed IgG-Capture BED-EIA, incorporates a branched peptide derived from 3 different subtypes to allow equivalent detection of antibodies of different subtypes. The competitive format of the assay allows detection of increasing proportion of HIV-1 IgG for almost 2 years after seroconversion. This is different from what is normally observed in a conventional EIA (with antigen coated plates) that plateaus soon after seroconversion. This assay will be important for HIV prevention activities, targeting resources, and evaluation of ongoing interventions.

Potential Commercial Applications: Competitive Advantages:
  • HIV clinical serodiagnostics
  • Informing clinical decision-making
  • Public health/HIV monitoring programs and incidence surveillance
 
  • Ready for commercialization
  • Simple and high-throughput capable
  • Detects HIV-1 subtypes prevalent in N. America, Europe, Japan, Thailand, Australia, and also central and E. Africa


Development Stage:
In vitro data available

Related Invention(s):
E-357-2013-0
E-358-2013-0


Inventors:

Steve McDougal (CDC)  ➽ more inventions...

Chou-Pong Pau (CDC)  ➽ more inventions...


Intellectual Property:
Research Tool – Patent protection is not being pursued for this technology.

Publications:
Parekh BS, et al. PMID 20954834
Dobbs T, et al. PMID 21832016
Parekh BS, et al. PMID 11860677
Dobbs T, et al. PMID 15184443
Nesheim S, et al. PMID 15989458

Licensing Contact:
Jeremiah Mitzelfelt,
Email: jeremiah.mitzelfelt@nih.gov
Phone: 301-443-8518

OTT Reference No: E-555-2013-0
Updated: Jan 29, 2014